The reissued EUA is for the qualitative detection of nucleic acid from SARS-CoV-2 in human oropharyngeal swab, nasopharyngeal swab, and anterior nasal swab specimens.
COVID-19-related business contributed $288 million in revenues during the quarter, offsetting a 6 percent year-over-year decline in non-COVID-19-related revenues.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
Qiagen has benefited from unexpected tailwinds due to COVID-19 testing and envisions post-pandemic growth with recently acquired NeuMoDx as a key contributor.
The firm noted that this is the first EUA for saline oral rinse collection used for SARS-CoV-2 testing, adding to its other approved collection methods.
